1 / 1

lapatinib(Tykerb)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Novartis

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

lapatinib(Tykerb) Instructions:Uses,Dosage, Side Effects

TYKERB® (lapatinib) is an oral, small molecule tyrosine kinase inhibitor manufactured by Novartis. It selectively targets and inhibits the intracellular tyrosine kinase domains of both HER2 (ErbB2) and EGFR (ErbB1) receptors. It is formulated as 250 mg film-coated tablets and is used in combination regimens for the treatment of specific types of advanced HER2-positive breast cancer.

Generic name

lapatinib(Tykerb)

English name

lapatinib

Alternative Names

Tykerb

Drug prices

Indications

Lapatinib in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapies including anthracyclines, taxanes, and trastuzumab. (Usage restriction: Before initiating treatment with lapatinib combined with capecitabine, patients must have experienced disease progression during trastuzumab treatment.)

Lapatinib in combination with letrozole is indicated for the treatment of postmenopausal women with hormone receptor-positive, metastatic breast cancer that overexpresses the HER2 receptor. The combination of lapatinib with an aromatase inhibitor (letrozole in this case) has not been compared with trastuzumab-containing chemotherapy regimens for the treatment of metastatic breast cancer.

Therapeutic Target

EGFR＋HER2

Active Ingredients

lapatinib

Dosage form

TABLET

specifications

250mg * 30 tablets

Description

Dosage and Administration

With capecitabine: 1,250 mg (5 tablets) orally once daily on days 1–21 of a repeating 21-day cycle.

With letrozole: 1,500 mg (6 tablets) orally once daily continuously.

Administer at least one hour before or after a meal. Do not divide daily dose.

Dose adjustments are required for hepatic impairment, severe diarrhea, and concomitant use with strong CYP3A4 inhibitors or inducers.

CATEGORY NAVIGATION